Dose optimization of infliximab in patients with rheumatoid arthritis (Q38182728)

30 August 2017

title

Dose optimization of infliximab in patients with rheumatoid arthritis (English)

1 reference

30 August 2017

0 references

2

Filip van den Bosch

1 reference

30 August 2017

Rieke Alten

1

1 reference

30 August 2017

publication date

1 November 2013

1 reference

International Journal of Rheumatic Diseases

30 August 2017

published in

1 reference

30 August 2017

volume

17

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

5-18

1 reference

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

Treating rheumatoid arthritis to target: recommendations of an international task force

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

Developing a standardized definition for disease "flare" in rheumatoid arthritis (OMERACT 9 Special Interest Group).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

Double-blinded infliximab dose escalation in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

[Dose adjustment in patients treated with infliximab in routine rheumatologic care in Germany. Results from the Biologics Register RABBIT].

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

Anti-TNF treatments in rheumatoid arthritis: economic impact of dosage modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

Developing a Construct to Evaluate Flares in Rheumatoid Arthritis: A Conceptual Report of the OMERACT RA Flare Definition Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12202

21 January 2018

Identifiers

DOI

10.1111/1756-185X.12202

1 reference

30 August 2017

1 reference